D. Ross Camidge on the Development of a New Lung Cancer Drug

D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK).

D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK).

Camidge presented results from a study of brigatinib during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of nearly 30,000 oncology professionals in Chicago.

Related Content:

CURE TV
Common Questions on Medical Marijuana
‘Incredible’ That a One-Time Infusion of CAR-T Cell Therapy Induces Durable Responses in Acute Lymphoblastic Leukemia
Why It’s Important to Be a Well-Educated, Proactive Patient